Keymed Biosciences Full Year 2023 Earnings: EPS Misses Expectations

Keymed Biosciences (HKG:2162) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥354.1m (up 254% from FY 2022).
• Net loss: CN¥359.4m (loss widened by 17% from FY 2022).
• CN¥1.38 loss per share (further deteriorated from CN¥1.18 loss in FY 2022).

2162 Products In Clinical Trials

• Phase I: 4.
• Phase II: 6.
• Phase III: 5.

2162 Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Keymed Biosciences EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 20% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Keymed Biosciences (of which 1 is a bit concerning!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.